Agios Pharmaceuticals

Revenue visibility is improving but remains in the early innings of the thalassemia launch and is subject to access, REMS onboarding, and ex‑U.S. reimbursement pacing.

TTM product revenue is roughly $98 million with >90% gross margin, reflecting accelerating uptake in 1H26. Regulatory catalysts add both upside and uncertainty: the sickle cell sNDA has a Priority Review with a PDUFA date of November 1, 2026 and will require confirmatory evidence; outcomes there could materially reshape the trajectory.

Competitive dynamics are mixed: Pfizer’s Oxbryta withdrawal removed one oral SCD competitor, but high‑priced gene therapies are expanding and may siphon subsets of eligible patients. Geographic diversification (U.S., EU, GCC) helps but ex‑U.S. access ramps are inherently lumpy.

Overall, predictability is moderate until the base broadens and cash burn declines.